RTI International, Waltham, Massachusetts, USA.
J Am Med Inform Assoc. 2012 May-Jun;19(3):439-42. doi: 10.1136/amiajnl-2011-000179. Epub 2011 Nov 18.
In a randomized trial of a clinical decision support system for drug prescribing for residents with renal insufficiency in a large long-term care facility, analyses were conducted to estimate the system's immediate, direct financial impact. We determined the costs that would have been incurred if drug orders that triggered the alert system had actually been completed compared to the costs of the final submitted orders and then compared intervention units to control units. The costs incurred by additional laboratory testing that resulted from alerts were also estimated. Drug orders were conservatively assigned a duration of 30 days of use for a chronic drug and 10 days for antibiotics. It was determined that there were modest reductions in drug costs, partially offset by an increase in laboratory-related costs. Overall, there was a reduction in direct costs (US$1391.43, net 7.6% reduction). However, sensitivity analyses based on alternative estimates of duration of drug use suggested a reduction as high as US$7998.33 if orders for non-antibiotic drugs were assumed to be continued for 180 days. The authors conclude that the immediate and direct financial impact of a clinical decision support system for medication ordering for residents with renal insufficiency is modest and that the primary motivation for such efforts must be to improve the quality and safety of medication ordering.
在一项针对大型长期护理机构中肾功能不全居民药物处方的临床决策支持系统的随机试验中,进行了分析以估计该系统的直接财务影响。我们确定了如果实际完成了触发警报系统的药物订单,与最终提交的订单相比,将会产生的成本,然后将干预组与对照组进行比较。还估计了由于警报而导致的额外实验室测试所产生的成本。药物订单保守地分配给慢性药物 30 天的使用期,抗生素为 10 天。结果发现药物成本略有降低,但实验室相关成本的增加部分抵消了这一降低。总体而言,直接成本降低(1391.43 美元,净减少 7.6%)。但是,基于替代药物使用时间估计的敏感性分析表明,如果假设非抗生素药物的订单持续 180 天,则成本降低高达 7998.33 美元。作者得出结论,对于肾功能不全患者的药物处方的临床决策支持系统的直接财务影响适度,此类努力的主要动机必须是提高药物处方的质量和安全性。